Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.


    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.


    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.



    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.


    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017, 106:25-29. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.


    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NEDlZ|RHfW6ldHnvckBCe3OjeR?= MkHZNlUh|ryP M2TmS|EhcA>? NVfydldJ[my3boTzJJRp\SCEW3HdVE1qdmS3Y3XkJIlv[3KnYYPlJIlvKHCqb4PwbI8uS2itMTDhcoQheGixc4Doc{1GWktiZYjwdoV{e2mxbh?= MnftNlU4PjlzOEG=
MCF-7  M2CyWWZ2dmO2aX;uJGF{e2G7 Mn;nNVAh|ryP MmXzNUBp NVe4[VBscW6qaXLpeJMhUUxvMUit[Y5p[W6lZXSgZ4VtdCCvaXfyZZRqd25? M2\mXlI2PzJ5MEGx
HepG2  MYPGeY5kfGmxbjDBd5NigQ>? M1XzO|ExKM7:TR?= NF\3d4M2KGh? MnLlZoxw[2u|IIDoc5NxcG:{eXzheIVlKE2DUFvzJIlv\HWlZXSgZpkh\XixZ3Xuc5V{KFSJRj5OtlE> MoHTNlU2PjB2OEi=
HepG2  NIjiNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTNlAh|ryP NU\jRXNNOjRiaB?= Mom0d5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJIFv\CCrbo\hd4lwdg>? M{LRZVI2PTZyNEi4
MDA-MB-231 NELaZZZHfW6ldHnvckBCe3OjeR?= M17qV|I2KM7:TR?= NHnCXG0zNTNiaB?= M1TWSoRm[3KnYYPld{BxNUWUS{GvNkBidmRiU{GwNGE1KGW6cILld5Nqd25? M1PudVI2PTV3OEe1
SW480 MnSzSpVv[3Srb36gRZN{[Xl? NHjxblgzOMLizszN NIPocmwyyqCq MWLy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=> NHn6c3ozPTR2N{ixOi=>
HCT-15 NVrFOpNxTnWwY4Tpc44hSXO|YYm= MX:xJIg> MnLwZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh NYrKbodFOjV2M{G0NlU>
HCT-15 M3XaPGFxd3C2b4Ppd{BCe3OjeR?= M{fMeFEhcA>? MVnhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{ NVLZdVVlOjV2M{G0NlU>
786-O NGHwWHFCeG:ydH;zbZMhSXO|YYm= NGL0Zpk2OMLizszN MmTNNlQhcA>? MUnwc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?= MX6yOFUxQDR5Nh?=
A498 M374V2Fxd3C2b4Ppd{BCe3OjeR?= NGfwNJg2OMLizszN Mn\zNlQhcA>? MlLjdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO= NVzsUYVROjR3MEi0O|Y>
NHBE MVXGeY5kfGmxbjDBd5NigQ>? NHHnUFczNzJyIN88US=> NEfvOY4zKGh? MoHYZZR1\W63YYTld{BKVC1|MzDzeIlufWyjdHXkJGNZS0x6L1nMMVghe2WlcnX0bY9v NVvTWlJ1OjR2N{m1NlY>
A375 NVryN2lrS2WubDDJcpZie2mxbjDBd5NigQ>? MVuxNQKBmzJyINM1US=> NVrx[otNOjRiaB?= MXjy[YR2[2W|IH3lcIFvd22jIHPlcIwhcW64YYPpc44> M{PvUVI1PDZ4MEO2
HBMEC MWTGeY5kfGmxbjDBd5NigQ>? NILkfm4yOCEQvF2= NGHINmoyKGh? MVXicI9kc3NiVlXHSk1qdmS3Y3XkJGVxcEF{IHX4dJJme3Orb36= Moe4NlQ1PTh7OEK=
HPAEpiCs  NHXWTWZHfW6ldHnvckBCe3OjeR?= NY\F[|BDOzBizszN MVmxJIg> NH2yS4pqdmirYnn0d{BVVkZvzsGgd5RqdXWuYYTl[EBxPDJxcES0JG1CWEticHjvd5Bpd3K7bHH0bY9v NFLpb|MzPDR2MUi3NC=>
BeWo NGP0XlVHfW6ldHnvckBCe3OjeR?= MXSxNOKh|ryP MXOyJIg> NILxR3pqdmirYnn0d{BGWktzL{K= MYWyOFQ{Ozh2Nh?=
PC3  MUTBdI9xfG:|aYOgRZN{[Xl? M3HZc|UxKM7:TR?= NHTvc|cxNjViaB?= M3TzeIlvcGmkaYTzJG1JYS12NEmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> NEG0eZEzPDR{NEi4PS=>
MCF-7 M{P5U2Z2dmO2aX;uJGF{e2G7 NWDtc4x3OTEEoN88US=> MVexNE8{OCCvaX6= M4rjSJJm\HWlZYOgeIhmKFWWUD3k[ZBmdmSnboSgSXJMKHCqb4PwbI9zgWyjdHnvci=> NVTkd2tnOjR|OUC4NVk>
HeLa NG\EXFFHfW6ldHnvckBCe3OjeR?= NGHtcHk2OCEQvF2= M1P3cFAvPSCq MYPicI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=> M4LV[FI1Ozd4OEK3
HL-60  MYHGeY5kfGmxbjDBd5NigQ>? MYSxNE8zOCEQvF2= MX2xJIg> MknmbY5pcWKrdIOgeIhmyqCQLjDjbIlv\W6|aYPlfJRz[WO2wrDpcoR2[2WmIHTp[oZmemWwdHnheIlwdiCrboTvJIdz[W63bH;jfZRmew>? MUSyOFM2PzB{MB?=
HL-60 MX;GeY5kfGmxbjDBd5NigQ>? M2PjNFIhyrWP MkL5NVYhcA>? MU\EUXNQ NIfJOHZqdmirYnn0d{B1cGViYYPzc4Nq[XSrb36gc4YheFN4MkGgVoFnNTFiYX7kJG5HSVSlMzygZY5lKHSqZTDSRU1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBvfWOuZXHyJG5HSVSlMx?= MlvDNlQ{OzByNki=
HEK 293 M3LpUWZ2dmO2aX;uJGF{e2G7 M4D4[lExKM7:TR?= MoD5OUBp M3Hj[mROW09? M3L4eIlvcGmkaYTzJHdvfC2rbnT1Z4VlKM7{LXPheIVvcW5xVFPGOEBi[3Srdnn0fUBidmRiboXjcIVieiEQsj3jZZRmdmmwIHHjZ5VufWyjdHnvci=> MWKyOFMzPDN4Nh?=
SW480 NHrneGhHfW6ldHnvckBCe3OjeR?= NWrqXGJZOTBizszN M1\qdlIxKGh? NVL3bFlzTE2VTx?= NIrOWol{fXCycnXzd4V{KHSqZTDDVnQh[WO2aY\peJk> NHfW[4UzPDN{NEO2Oi=>
HCSMCs NXTnfI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jodFExKM7:TR?= Mn\tNlQhcA>? NFvvUHZjdG:la4OgSmFDWDRvaX7keYNm\CCKQ1HTUWMheHKxbHnm[ZJifGmxbh?= MYGyOFMyOjN6MR?=
PANC-1 NE[yfItHfW6ldHnvckBCe3OjeR?= M323[lIxKM7:TR?= Mo[2OFghcA>? NI\tepNqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kDPnD[GIHnuJJJme3CxboPlJJRwKHSqZTDQVGFT|rUEoHHnc45qe3UEoB?= NXfJcYVlOjR{OUSxN|M>
A549 M{O5TmZ2dmO2aX;uJGF{e2G7 M3HoOFMxKM7:TR?= MXWwMlUhcA>? NGrnW|BFVVOR MnG1bY5pcWKrdIOgeIhmKHSqcn;tZolvNWmwZIXj[YQhUUxvOD;DXGNNQC2OdXOgZYN1cX[rdIm= M2e5d|I1Ojd5Nkm2
A549 NF7BOodHfW6ldHnvckBCe3OjeR?= NGDWXmY{OCEQvF2= MmTkNE42KGh? MYrEUXNQ M17RdolvcGmkaYTzJJRpem:vYnnuMYlv\HWlZXSgR{9GSlEQsjDUbJIzOzYEoIDoc5NxcG:{eXzheIlwdg>? M1vUfVI1Ojd5Nkm2
MC-3 NHXiU2FCeG:ydH;zbZMhSXO|YYm= MUmxNEDPxE1? M{HsRVI1KGh? MWrwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= Ml3TNlQzPzB3MkO=
Raji  NXO0RZRYTnWwY4Tpc44hSXO|YYm= NW\zPXJ4OTBizszN MoTkNUBp Mn7oZoxw[2u|IHjzRmFHTiCrbnT1Z4VlKEW{a{GvNkBxcG:|cHjvdplt[XSrb36= NIjsUIozPDJ4OU[zNC=>
Raji  NHTqc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGcVExKM7:TR?= M2S3blEhcA>? NUjr[5NicW6qaXLpeJMhfGinIHLhd4FtKG:{IHjzRmFHTi2|dHnteYxifGWmIHPlcIwheHKxbHnm[ZJifGmxbjDhcoQhfmmjYnnsbZR6 MXiyOFI3QTZ|MB?=
HT29 NED1PFNHfW6ldHnvckBCe3OjeR?= NFHuU3EyOCEQvF2= NGWxOHQzKGh? NFn3OFZqdmirYnn0d{Bw\iCMQVuyMEBGWktzL{KgZY5lKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?= MWCyOFI3PTJ7Mx?=
HepG2 M3f5W2Fxd3C2b4Ppd{BCe3OjeR?= NH\VS3gzOCEQvF2= MkPDNlQhcA>? NIHVSJJqdmirYnn0d{BGWktzL{KgdIhwe3Cqb4L5cIF1cW:wIHHu[EBmdmijbnPld{BXSjFvaX7keYNm\CCjcH;weI9{cXN? NYXaSGNyOjR{NEe5NFk>
HepG2 MV7GeY5kfGmxbjDBd5NigQ>? NHLReYUzOCEQvF2= NVnh[2QzOiCq M{DNfoVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= MlTENlQzPDd7MEm=
TE4 NUnycY9ZTnWwY4Tpc44hSXO|YYm= Mn[xNlAwPTBxMUCwJO69VQ>? M3PCXlQ5KGh? MnHTSG1UVw>? MkHmbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVLaUnJUOjR{NESwNlM>
TE1 NEC2WHBHfW6ldHnvckBCe3OjeR?= MmnpNlAwPTBxMUCwJO69VQ>? MmH6OFghcA>? MnmzSG1UVw>? NX\HWVhXcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUTaXmhlOjR{NESwNlM>
KYSE30 NGTaeolHfW6ldHnvckBCe3OjeR?= M{fEWlIxNzVyL{GwNEDPxE1? NGPMPHE1QCCq MkfpSG1UVw>? Mn20bY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXHBe25TOjR{NESwNlM>
TE3 NVPOOnJWTnWwY4Tpc44hSXO|YYm= MlnSOVAh|ryP Mn;0OFghcA>? M2fTe2ROW09? M373S5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL NWexNpRJOjR{NESwNlM>
TE4 MYHGeY5kfGmxbjDBd5NigQ>? NHz5e2c2OCEQvF2= NFTpe4g1QCCq MV7EUXNQ M1i0PZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEiOQTDjcIF{eyCL NFrnSIszPDJ2NECyNy=>
KYSE30 MlnISpVv[3Srb36gRZN{[Xl? MonhOVAh|ryP MniwOFghcA>? NGXzZmVFVVOR NI\GUVJ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= Mmn4NlQzPDRyMkO=
MKN7 MWLGeY5kfGmxbjDBd5NigQ>? M2XwV|UxKM7:TR?= M1vpelQ5KGh? MkLiSG1UVw>? NXTtUmNxcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NVyzUWJzOjR{NESwNlM>
OE19 NEDrdphHfW6ldHnvckBCe3OjeR?= Moe2OVAh|ryP MWO0PEBp M3PWWWROW09? NF\GOYhqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz M{PxflI1OjR2MEKz
KATOIII  MVzGeY5kfGmxbjDBd5NigQ>? M4LZXFUxKM7:TR?= Mnv5OFghcA>? M4i1dWROW09? NYTyR3BDcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> M2LBTlI1OjR2MEKz
NCI-N87  MkL6SpVv[3Srb36gRZN{[Xl? NVLYRoJFPTBizszN M1rUWFQ5KGh? Mki4SG1UVw>? NX3ZSnhPcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MVyyOFI1PDB{Mx?=
SGC-7901  M4DmUmFxd3C2b4Ppd{BCe3OjeR?= MWCyNEDPxE1? M3uwcVI1KGh? Mon3bY5pcWKrdIOgR3AudWWmaXH0[YQh[XCxcITvd4l{ MX2yOFI1OTN3MR?=
MG-63 MVnGeY5kfGmxbjDBd5NigQ>? NUnxV41FOjBizszN M2rT[FAvPSCq NWn1NZNU[myxY3vzJJRp\SCFSD3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKEWOS{GgdJJwfGWrbjDlfJBz\XO|aX;u M1uzVVI1OjN7NkSw
ARPE-19 MV7GeY5kfGmxbjDBd5NigQ>? M1y1NVIxKM7:TR?= NVTJeZo{OC53IHi= NYLjPY5icW6qaXLpeJMhSXCnbHnuMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzcyCjbnSgRYt1 NIe2NVUzPDJ{N{mxPC=>
CRL-2302 MnzwSpVv[3Srb36gRZN{[Xl? MYSyNEDPxE1? NWXudll[OC53IHi= NF;VbWlqdmirYnn0d{BCeGWuaX6tbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsKGGwZDDBb5Q> M1qweVI1OjJ5OUG4
MCF-7 NGrtSlJHfW6ldHnvckBCe3OjeR?= NELHSXMzOCEQvF2= MYqxJIg> NHTyXWxi[m:uaYPo[ZMh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUlugZ48ufHKnYYTt[Y51KHerdHigZ49vcnWpYYTl NIrVcW8zPDJzNkK4PS=>
DLD-1  M{XQXmZ2dmO2aX;uJGF{e2G7 Mn7hNlDDqM7:TR?= MYK0PEBp MmfxdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD MlG2NlQzOTF3OEG=
HT-29 MYnGeY5kfGmxbjDBd5NigQ>? NXLrZmZzOjEEoN88US=> NVvWTGRmPDhiaB?= NUXhN49xemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE NHrzPXQzPDJzMUW4NS=>
7402 NVP5To8ySXCxcITvd4l{KEG|c3H5 NInqT5M{OCEQvF2= NUf1UZdLPSCm MmTx[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NWjtd21{OjR{MUGyOVM>
7721 M3fjbWFxd3C2b4Ppd{BCe3OjeR?= MniwN|Ah|ryP NHnPOXg2KGR? M1y2XIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M3m2OFI1OjFzMkWz
SGC7901  NHH0NWpCeG:ydH;zbZMhSXO|YYm= MonLOVDDqM7:TR?= M4rIeFI1NzR6L{eyJIg> MlLMSG1UVw>? NE[2R4dqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= MmHwNlQyPzh{NEC=
SMMC7721 NGr1S4VHfW6ldHnvckBCe3OjeR?= NFv6RWQzPS93MDFOwG0> MYWyOEBp M3uwN5N2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM|LDqA>? M2faSlI1OTZ6MEW2
MCF-7 M3rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflWWVDOTBizszN MkjNOFhp NXjIRXk3TE2VTx?= NV;wU|lXemW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R? NESwbXMzPDF4M{SwOC=>
Caco-2 Mln2SpVv[3Srb36gRZN{[Xl? MXe1NOKh|ryP MmT1OFhp M{LQWWROW09? NFvnSlZmdmijbnPld{B1cGVibWLORUBt\X[nbIOgc4bDqFOFTl6xRUxHYFmGMz|CpGxEXC{EoFzPXEzDqEiLRkPBMOKhYkdzNj|CpHBFTT[DwrDhcoTDqEyJQVzTNVbDqGenbnXzxsBkdy22cnXheIVlKHerdHigSIV5 NWXaTWJHOjRzNkG2PVU>
HAECs MVXGeY5kfGmxbjDBd5NigQ>? NH34UVcyOCEQvF2= NGjpVWQyKGh? MoDtxsBifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKEmFQV2tNUBidmRiVlPBUU0yKGW6cILld5Nqd25? NXS2ZmlEOjRzM{S2OVc>
Ca9-22 MUnGeY5kfGmxbjDBd5NigQ>? NWDr[pM1OyEQvF2= M4TyXlEhcA>? M2fvRYFjd2yrc3jld{B1cGViYXLpcIl1gSCxZjDIZnIhfG9iaX7keYNmKEmOLUigdJJw\HWldHnvci=> Mlf1NlQyOjZ3M{K=
Ca9-22 NH;R[VlHfW6ldHnvckBCe3OjeR?= NHrxU5Y{KM7:TR?= M1HSNFEwOiCq NFTSW|Vz\WS3Y3XzJGhjWi2rbnT1Z4VlKEGWRj2yJJBpd3OyaH;yfYxifGmxbh?= NY[4Sld[OjRzMk[1N|I>
AGS NV\2em1lTnWwY4Tpc44hSXO|YYm= NX3NTWhIOTBizszNxsA> MX2wMlUhcA>? MnzabY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n MofZNlQyODZzNk[=
Caco-2  MkPwRZBweHSxc3nzJGF{e2G7 MnPINVDDqM7:TR?= NUPGemxXOjUEoHi= NUjzOoRM\GWlcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhPS2IVR?= NE\4eGwzPDB7NUi2Ny=>
HCT-8 MWfBdI9xfG:|aYOgRZN{[Xl? NXjTZlh5OTEEoN88US=> NIS2TWwzPMLiaB?= MmjC[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? NUTscGY3OjRyOUW4OlM>
A549 M4nUPGZ2dmO2aX;uJGF{e2G7 MmL1OVDDqM7:TR?= NVLjd2t[OiCq MmPvZoxw[2u|IFXST{BxcG:|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R MnGwNlQxPjd5Mke=
HPMC MVXGeY5kfGmxbjDBd5NigQ>? NFXNU3cyOMLizszN M{XlWlQ5KGh? MVvy[ZZmenOnczD0bIUh[2ijbnfld{BqdiClZXzsJI1wenCqb3zv[5khcW6mdXPl[EBjgSCKR2DEVy=> Ml\5NlQxPDJ6M{i=
HPMC MWfBdI9xfG:|aYOgRZN{[Xl? MmX3NVDDqM7:TR?= NGrtNVIzPMLiaB?= NX25Oo1OemW4ZYLz[ZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKR2DEVy=> NUmyWYNyOjRyNEK4N|g>
MGC803  NVzxS4d{SXCxcITvd4l{KEG|c3H5 M{PVSlIxyqEQvF2= MWqxJIg> NYL2bHNxcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS NHX3c2gzPDB{N{e1NC=>
SGC7901 MmnaRZBweHSxc3nzJGF{e2G7 MUCyNOKh|ryP NFi1T3gyKGh? NIDMfmRqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= NH\NcGozPDB{N{e1NC=>
G292  Mn7rRZBweHSxc3nzJGF{e2G7 MYOzNOKh|ryP M2DNb|IhcA>? NILRcW9z\XO2b4Lld{Bk[XC|YXnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp NIDte5IzPDBzMkmzNC=>
HepG2 NGC3empHfW6ldHnvckBCe3OjeR?= MX:0NEDPxE1? M1rEVFYwOTJiaB?= NGP5UndqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW|c3nvckBjgSCSTB?= MmfSNlM6PDJ6NUG=
HUVECs M2DiSmZ2dmO2aX;uJGF{e2G7 M4mzeVI2KM7:TR?= NXXjcZRHOSCq MlrzbY5kemWjc3WgUmYu|rqEIIC2OUBvfWOuZXHyJJRz[W6|bH;jZZRqd25? M{m3OFI{QTBzMEC4
LNCaP  MnjWSpVv[3Srb36gRZN{[Xl? MofMNVAh|ryPwrC= M2i4TFEhcA>? M{jtSoRm[3KnYYPld{B1cGViRVfGJJVxemWpdXzheIVlKHBvWVKtNS=> M3nHTVI{QDN6M{G4
HL60  NYHIc5R5TnWwY4Tpc44hSXO|YYm= Mk\iNlDDqM7:TR?= NWTVVmtPPzJiaB?= MXXEUXNQ NWTqU|U2cW6qaXLpeJMh\GG|YYTpcoljNWmwZIXj[YQhS0RzMXKg[ZhxemW|c3nvci=> NHfTWYMzOzh{NUW4OS=>
NB4  MWjGeY5kfGmxbjDBd5NigQ>? M1HIb|ExKM7:TdMg MVy3NkBp NETGe|JFVVOR MkjPbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= NUPPeHl1OjN6MkW1PFU>
EPOR/CR3 M1LG[GZ2dmO2aX;uJGF{e2G7 MV[1NOKh|ryP MlPKN{Bp NVeyeXZoemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> NUKz[4FjOjN6MkC3N|E>
HUASMCs MWrGeY5kfGmxbjDBd5NigQ>? MXOxNEDPxE4EoB?= NVPXU2pvOjRiaB?= NILUOm5lcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= NETzZ2IzOzhzNkS2PC=>
HUASMCs MVXGeY5kfGmxbjDBd5NigQ>? M333PVExKM7:TdMg M1fEPFI1KGh? MnzRbY5pcWKrdIOgRY5oKEmLLXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBt\X[nbB?= NIDTSYQzOzhzNkS2PC=>
SGC7901 NEjTTm9HfW6ldHnvckBCe3OjeR?= MkfmNVAh|ryPwrC= M3jLc|I1KGh? MUXpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> NUK3SY1rOjN5OUK1PFg>
MKN45 NXXDT3A6TnWwY4Tpc44hSXO|YYm= M3;kRVExKM7:TdMg NG\zU3IzPCCq NVX5OHlOcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheGixc4Doc5J6dGG2ZXSgSXJMOS9{ MonhNlM4QTJ3OEi=
SGC7901 NWLsbVM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7oS20yOCEQvF5CpC=> M{fKcFI1NzR6L{eyJIg> MYHpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>? MoPvNlM4QTJ3OEi=
MKN45 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm4XHcyOCEQvF5CpC=> MXuyOE81QC95MjDo NV7TSHRUcW6qaXLpeJMh[2WubDDndo94fGhiY3:teJJm[XSnZDD3bZRpKESDUGS= MYWyN|c6OjV6OB?=
SGC7901 NFfnUpRCeG:ydH;zbZMhSXO|YYm= Mny3NVAh|ryPwrC= NWDMW|h2OjRiaB?= NITVeGdqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?= NX3wVFZIOjN5OUK1PFg>
MKN45 NED6[4pCeG:ydH;zbZMhSXO|YYm= MUexNEDPxE4EoB?= NEnZVlczPCCq M3TtcYlv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NVnjeFZwOjN5OUK1PFg>
BxPC-3 cells MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyyNOKh|ryP MX2wMlUhcA>? MVvpcohq[mm2czDWSWdHNUFvcnXneYxifGWmIFjVWmVEKGe{b4f0bEBidmRidIXi[UBnd3KvYYTpc44hcW6mdXPl[EBjgSCSQWKtNkBCWA>? NY\oT4lVOjN5NkSwOFY>
NB4  MmfxRZBweHSxc3nzJGF{e2G7 MnXYNVAwOjBxNkCg{txO NF\2RYsyNjViaB?= MX7EUXNQ NHPa[Fhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTl[EB4cXSqIGDhZ4xqfGG6ZXy= M1;KN|I{PzN3NUSx
HepG2  MXfGeY5kfGmxbjDBd5NigQ>? NHjnbpczOMLizszN MWKyOEBp M2q2O4lvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu NFH2cpAzOzdyN{[wPS=>
KG-1  MlrHRZBweHSxc3nzJGF{e2G7 NF7TclMzOMLizszN MXOxNkBp MUPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx NVO3RoNZOjN5ME[2PVE>
AML 1# NEKzNmpCeG:ydH;zbZMhSXO|YYm= NIDjUIozOMLizszN NY\kSo5[OTJiaB?= NGj5VnRmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy NWH3cZlSOjN5ME[2PVE>
A2780  MWDGeY5kfGmxbjDBd5NigQ>? NHXLUYszOMLizszN MkniNUBp M4jVd4Jtd2OtczDEWGNFNWmwZIXj[YQhTFJ3IHX4dJJme3Orb36= NVvmR3RFOjN4OU[4OlI>

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]


Kinase Assay:


+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:


+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28


CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID